Quarterly Progress Report

Year   
Normalized   

Quarterly Progress Report (QPR) on age-group wise service deliveries and information on distribution of Iron and Folic Acid (IFA) syrup and tablets- Pink, Blue & Red, Albendazole tablets among the 6 focused age groups. The information is derived on the basis of data updates available from HMIS indicators (Numerator) calculated using the eligible age specific respective denominators for each age group. *The GOI quarter reporting year starts from April and ends in March of the subsequent year (Q1-April to June, Q2-July to September, Q3- October to December and Q4 January to March (of subsequent year)).

Service Delivery in Percentage

India

Children 6-59 months


YearUpto Q1Upto Q2Upto Q3Upto Q4
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2020-219.10.00.00.0
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2019-209.411.114.014.9
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2018-197.47.77.88.3
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2017-185.46.16.36.6
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2020-210.30.00.00.0
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2019-200.62.92.42.9
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2018-191.12.31.72.3
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2017-180.51.91.62.1
Children 5-9 years


YearUpto Q1Upto Q2Upto Q3Upto Q4
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2020-213.40.00.00.0
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2019-2017.421.924.930.2
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2018-197.77.69.314.9
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2017-188.18.78.48.0
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2020-210.30.00.00.0
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2019-201.33.63.44.9
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2018-191.32.52.23.7
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2017-180.92.52.02.2
Adolescents 10-19 years


YearUpto Q1Upto Q2Upto Q3Upto Q4
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-213.60.00.00.0
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2027.933.836.840.6
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1916.917.918.828.0
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1818.920.621.521.7
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2020-214.50.00.00.0
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2019-2016.419.520.222.7
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2018-197.17.08.412.1
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2017-184.74.84.96.4
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2020-210.70.00.00.0
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2019-202.75.55.77.0
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2018-191.53.33.15.6
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2017-182.15.03.94.4
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2020-210.30.00.00.0
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2019-202.53.53.63.9
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2018-190.81.51.92.8
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2017-180.71.41.21.7
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-213.70.00.00.0
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2027.731.435.439.7
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1916.818.319.129.1
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1819.221.222.522.6
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-213.60.00.00.0
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2027.835.938.241.6
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1916.917.018.326.6
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1818.620.021.021.1
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2020-210.70.00.00.0
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2019-202.75.65.77.1
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2018-191.73.53.36.0
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2017-182.25.24.04.7
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2020-210.70.00.00.0
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2019-202.65.35.67.0
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2018-191.33.12.85.1
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2017-182.04.93.74.3
Pregnant Women


YearUpto Q1Upto Q2Upto Q3Upto Q4
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets
2020-2185.60.00.00.0
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets
2019-2087.288.990.890.3
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets
2018-1985.991.785.484.8
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets
2017-1870.760.675.277.7
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2020-2143.90.00.00.0
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2019-2039.341.042.844.4
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2018-1933.138.035.837.5
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2017-1824.822.228.629.7
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2020-2163.30.00.00.0
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2019-2071.772.773.471.8
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2018-1967.877.270.870.8
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2017-1864.355.867.569.3
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2020-213.00.00.00.0
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2019-203.73.84.03.7
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2018-193.44.04.13.7
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2017-183.32.93.73.7
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2020-211.60.00.00.0
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2018-191.72.12.02.0
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2017-181.51.31.71.6
Lactating Women 0-6 months


YearUpto Q1Upto Q2Upto Q3Upto Q4
HMIS 6.3:
Percentage of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2020-2130.90.00.00.0
HMIS 6.3:
Percentage of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2019-2040.644.947.549.0
HMIS 6.3:
Percentage of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2018-1934.838.939.241.6
HMIS 6.3:
Percentage of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2017-1826.931.333.834.4

Stock Availability

Stocks Available


YearUpto Q1Upto Q2Upto Q3Upto Q4
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2020-2127.50.00.00.0
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2019-2044.444.946.752.4
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2018-1926.231.132.646.5
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2017-1830.327.530.035.6
HMIS 19.6:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2020-2110.50.00.00.0
HMIS 19.6:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2019-2025.429.730.633.2
HMIS 19.6:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2018-1929.627.629.035.1
HMIS 19.6:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2017-1819.128.929.228.2
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2020-2116.50.00.00.0
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2019-2040.842.649.252.6
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2018-1941.738.036.946.1
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2017-1843.434.632.135.5
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2020-2121.10.00.00.0
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2019-2050.857.558.062.7
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2018-1952.141.740.552.2
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2017-1817.717.716.720.7
HMIS 19.15:
Percentage of stocks available for Albendazole tablets
2020-2145.90.00.00.0
HMIS 19.15:
Percentage of stocks available for Albendazole tablets
2019-2094.687.975.678.7
HMIS 19.15:
Percentage of stocks available for Albendazole tablets
2018-1983.466.664.686.9
HMIS 19.15:
Percentage of stocks available for Albendazole tablets
2017-1830.333.738.047.7
Reporting Status


YearUpto Q1Upto Q2Upto Q3Upto Q4
HMIS A.1:
Percentage of facilities reporting in the quarter
2020-2195.00.00.00.0
HMIS A.1:
Percentage of facilities reporting in the quarter
2019-2095.095.095.095.0
HMIS A.1:
Percentage of facilities reporting in the quarter
2018-1994.395.095.095.0
HMIS A.1:
Percentage of facilities reporting in the quarter
2017-1895.095.095.095.0